Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and efficacy of OKG-0301 in the treatment of acute adenoviral conjunctivitis.